Ilya Petrou, MD, is a contributing writer for Dermatology Times.
’Beacon of hope’: Study finds melanocytes are target in alopecia areata
September 15th 2009Portland, Ore. - A recent study confirms that the numbers of follicular melanocytes are significantly decreased in patients suffering from alopecia areata.This new insight into the often severe and psychologically burdensome disease serves as a beacon of hope for patients, as researchers begin to home in on a more precise etiology that may open the door for more targeted treatments. Past research has implicated follicular melanocytes to be the target structure in at least a proportion of patients suffering from alopecia areata.
Cosmeceuticals: Scrutinize ingredients, pick and choose best products
September 9th 2009New York - Cosmetic patients today have a multitude of cosmeceuticals from which to choose, and each product claims to raise the bar in its effectiveness in skin rejuvenation. Many of these products do have some degree of effectiveness, and yet others may be the cause of hardship in terms of eliciting an irritant or allergic contact dermatitis in the unfortunate user. According to one expert, physicians need to scrutinize the ingredients of these cosmeceuticals and carefully pick and choose among the vast array of products for the benefit of their patients.
Pathogenesis of vitiligo: Immunomodulating therapies favored course of action
September 9th 2009Edmonton, Alberta - Although several different theories exist with regard to the pathogenesis of vitiligo, an immune basis appears to be the most favored mechanism, with cytokines and other chemical mediators playing a center role in disease development and progression. As a result, immunomodulating therapies such as tacrolimus (Protopic, Astellas) are employed.
’Crystel’ clear: Study shows etanercept improves depression, anxiety in psoriasis patients
September 2nd 2009International report - Etanercept therapy helps to improve symptoms of depression and anxiety long-term in patients suffering from moderate-to severe psoriasis, according to the results of the Crystel study.
Avoiding steroidal addiction: Consider calcineurin inhibitors first
August 31st 2009Sheffield, England - New research data demonstrates that mild, moderate and potent strengths of topical corticosteroids (TCS) cause a thinning of the stratum corneum, particularly when applied for longer periods of time, whereas topical calcineurin inhibitors show no negative change in the integrity of the skin barrier.
Activating cutaneous vitamin D: Low-dose UVB strengthens epidermal barrier, antimicrobial function
August 31st 2009Wonju, South Korea - While high-dose UVB is detrimental to the epidermal permeability barrier, low-dose UVB can be therapeutic in mending a defective epidermal barrier and antimicrobial function, such as in atopic dermatitis, according to one dermatologist.
Unique development: Pyoderma gangrenosum appear during ulcerative colitis
August 4th 2009In a recent case study, a patient receiving infliximab for the treatment of ulcerative colitis paradoxically developed widespread pyoderma gangrenosum lesions, a disease which normally responds well to this biologic therapy.
Managing surgical wounds: Laser-activated tissue repair trumps standard surgical closure
August 4th 2009A recent study ushers in the era of molecular surgery as laser-assisted "nanosuturing" proves to be superior to traditional suture closing techniques not only in terms of cosmesis but also in the tensile strength and quality of wound closure. According to Dr. Sandy Tsao, who spearheaded the first human clinical trial, this novel technique is set to change the way physicians approach and manage surgical wounds in the future.
Systemic therapy: Doctors eye fresh approaches to cutaneous lupus
August 4th 2009Both topical and systemic therapies are used in patients with cutaneous lupus erythematosus. According to one expert, the antimalarials are still the safest and often effective treatment approach. However, newer therapies may offer some hope in those especially challenging to treat recalcitrant cases of CLE.
A watchful eye: Population-based study refutes anecdotes that cutaneous lupus is on the rise
August 4th 2009The results of a recent population-based study confirms that the incidence of Cutaneous lupus erythematosus is not two to three times higher than the incidence of the more severe systemic lupus erythematosus form of the autoimmune disease, as anecdotally once thought.
Post-transplant disorder a risk: Lymphoproliferative condition can be life-threatening
February 1st 2009Post-transplant lymphoproliferative disorder is lymphocyte proliferation in patients following post-transplant immunosuppression and is the most common neoplasm in pediatric organ transplant recipients. Due to the increased frequency of organ transplantation, dermatologists should be aware of the cutaneous presentation, as a timely diagnosis and treatment is crucial for a favorable prognosis.
Agressive carcinogenisis: Case studies link extraocular sebaceous carcinoma, immunosuppression
February 1st 2009Organ transplant recipients (OTRs) have an increased risk of carcinogenesis most likely due to the immunosuppressive medication they need to take. Sebaceous carcinoma is a rare occurrence, however, as witnessed in two recent case studies, this highly aggressive malignant tumor can occur in immunosuppressed OTRs, making the thorough screening programs a high priority in these patients.
Actinic keratoses: Experimental topical gel offers effective short treatment regime
February 1st 2009Ingenol mebutate is a novel approach for the treatment of actinic keratoses. This new topical approach successfully treats AKs in only two or three days, - a much shorter therapeutic regimen compared to the current readily used topical approaches, such as solaraze, 5-FU and imiquimod, and, therefore, also increases patient compliance.
Anti-acne peel: Innovative topical therapy effective in patients with mild-to-moderate lesions
February 1st 2009A novel peel is proving to be very effective in the treatment of comedonic as well as mild-to-moderate acne lesions. This approach could spare acne patients from repeated antibiotic therapies for considerably benign cosmetic lesions.